secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001628280-25-013984
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo reports 2024 net loss of $35.1M; cash of $134.5M funds into at least 2027
-------------------------------------------------------------------------------

- Cash and equivalents $134.5M at Dec 31, 2024 vs $7.4M in 2023; runway into at least 2027.
- Net loss $35.1M in 2024 ($7.94 basic EPS) vs $31.5M loss in 2023; diluted EPS -$20.91.
- R&D expense $24.4M, up $10.7M, driven by Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa.
- Topline data from Phase 2 LOTUS trial expected in 2026; second indication for AVTX-009 planned.
- Appointed Jennifer Riley as Chief Strategy Officer effective January 1, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828025013984/0001628280-25-013984-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828025013984/avtx-20250320.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-013984

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer